Delcath Systems, Inc. (NASDAQ:DCTH – Get Free Report) insider Vojo Vukovic acquired 60,000 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were purchased at an average cost of $2.48 per share, for a total transaction of $148,800.00. Following the acquisition, the insider now owns 60,000 shares of the company’s stock, valued at approximately $148,800. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Delcath Systems Stock Performance
NASDAQ:DCTH traded up $0.25 during midday trading on Monday, reaching $2.70. The stock had a trading volume of 785,844 shares, compared to its average volume of 716,830. The company has a quick ratio of 1.53, a current ratio of 3.30 and a debt-to-equity ratio of 0.08. The stock has a market cap of $59.52 million, a P/E ratio of -0.81 and a beta of 0.51. The firm has a fifty day simple moving average of $3.62 and a two-hundred day simple moving average of $4.92. Delcath Systems, Inc. has a 12-month low of $2.25 and a 12-month high of $7.99.
Delcath Systems (NASDAQ:DCTH – Get Free Report) last issued its earnings results on Monday, November 13th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.10). Delcath Systems had a negative net margin of 2,079.17% and a negative return on equity of 2,571.64%. The firm had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $0.68 million. On average, equities analysts expect that Delcath Systems, Inc. will post -2.59 EPS for the current year.
Hedge Funds Weigh In On Delcath Systems
Analysts Set New Price Targets
A number of research analysts recently issued reports on DCTH shares. BTIG Research raised their price target on Delcath Systems from $19.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, August 15th. Roth Mkm lifted their target price on shares of Delcath Systems from $10.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, August 16th. HC Wainwright increased their price target on shares of Delcath Systems from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, August 15th. StockNews.com assumed coverage on shares of Delcath Systems in a research note on Thursday, October 5th. They issued a “sell” rating on the stock. Finally, Canaccord Genuity Group upped their target price on shares of Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, September 7th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $18.00.
About Delcath Systems
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- Five stocks we like better than Delcath Systems
- 3 Small Caps With Big Return Potential
- The most upgraded stocks in November have two things in common
- What is a Non-Fungible Token (NFT)? Definition and How it Works
- Monday.com rocked earnings like it’s the weekend
- What is Forex and How Does it Work?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.